Abstract:BackgroundIn the current study, we sought to characterise the methylation haplotypes and nucleosome positioning patterns of placental DNA and plasma cell-free DNA of pregnant women with early-onset preeclampsia using whole genome bisulphite sequencing (WGBS) and methylation capture bisulphite sequencing (MCBS) and further develop and examine the diagnostic performance of a generalised linear model (GLM) by incorporating the epigenetic features for early-onset preeclampsia.MethodsThis case-control study recruited pregnant women aged at least 18 years who delivered their babies at our Hospital. In addition, non-pregnant women with no previous history of diseases were included. Placental samples of the villous parenchyma were taken at the time of delivery and venous blood was drawn from pregnant women during non-invasive prenatal testing at 12-15 weeks of pregnancy and nonpregnant women during the physical check-up. WGBS and MCBS were carried out of extracted genomic DNA. Then, we established the GLM by incorporating preeclampsia-specific methylation haplotypes and nucleosome positioning patterns and examined the diagnostic performance of the model by receiver operating characteristic (ROC) curve analysis.ResultsThe study included 135 pregnant women and 50 non-pregnant women. Our high-depth MCBS revealed notably different DNA methylation and nucleosome positioning patterns between women with and without preeclampsia. Preeclampsia-specific hypermethylated sites were found predominantly in the promoter regions and particularly enriched in CTCF on the X chromosome. Totally, 2379 preeclampsia-specific methylation haplotypes were found across the entire genome. ROC analysis showed that the area under the ROC curve (AUC) was 0.938 (95%CI 0.877, 1.000). At a GLM cut-off of 0.341, the AUC was the maximum, with a sensitivity of 95.6% and a specificity of 89.7%.ConclusionPregnant women with early-onset preeclampsia exhibit DNA methylation and nucleosome positioning patterns in placental and plasma DNA. Early-onset preeclampsia is a potentially dangerous condition that can have a profound impact on the health of both the expectant mother and her unborn child. This condition is particularly concerning because it's challenging to predict who may be affected using conventional methods such as monitoring blood pressure. In our research, we've developed an innovative, non-invasive approach to predict the onset of early preeclampsia. We do this by analysing the genetic material of the developing baby, which can be found in the mother's blood. Our method has shown remarkable accuracy in our testing populations, and its implications are substantial. By providing an early warning system, this breakthrough can benefit pregnant women immensely. It means that early-onset preeclampsia can be identified and addressed well before it becomes a serious health threat. This allows for timely medical interventions and treatments, significantly improving the well-being of both mothers and their precious little ones.

Detection of Global DNA Methylation and Paternally Imprinted H19 Gene Methylation in Preeclamptic Placentas.

Hypermethylation of the Hla-G Promoter is Associated with Preeclampsia

Alteration in Methylation Level at Differential Methylated Regions of MEST and DLK1 in Fetus of Preeclampsia.

Methylation Levels at Igf2 and Gnas Dmrs in Infants Born to Preeclamptic Pregnancies

Methylation pattern of H19 exon 1 is closely related to preeclampsia and trophoblast abnormalities.

Epigenome-wide association data implicate fetal/maternal adaptations contributing to clinical outcomes in preeclampsia.

Up-Regulated Expression And Aberrant Dna Methylation Of Lep And Sh3pxd2a In Pre-Eclampsia

The role of DNA methylation in placental development and its implications for preeclampsia

Genome-Wide Mapping of 5mc and 5hmc Identified Differentially Modified Genomic Regions in Late-Onset Severe Preeclampsia: A Pilot Study.

Alteration in Methylation Level at 11Β-Hydroxysteroid Dehydrogenase Type 2 Gene Promoter in Infants Born to Preeclamptic Women

High-throughput methylome analysis reveals differential methylation for early and late onset preeclampsia for mothers and their children

Comprehensive Analysis of Differently Expressed and Methylated Genes in Preeclampsia

Preeclampsia is Associated with Hypermethylation of IGF-1 Promoter Mediated by DNMT1.

Distinct DNA Methylation Signatures in Maternal Blood Reveal Unique Immune Cell Shifts in Preeclampsia and the Pregnancy-Postpartum Transition

14-3-3 tau (YWHAQ) gene promoter hypermethylation in human placenta of preeclampsia

Epigenetic phenotype of plasma cell-free DNA in the prediction of early-onset preeclampsia

Preeclampsia is Associated with Decreased Methylation of the GNA12 Promoter.

A longitudinal epigenome-wide association study of preeclamptic and normotensive pregnancy

[Variation of Long-Chain 3-Hydroxyacyl CoA Dehydrogenase DNA Methylated Modification and Correlation with Gene Mrna Expression of Early-Onset Preeclampsia, HELLP Syndrome and Antiphospholipid Syndrome in Trophoblast Cells of Placenta].

Comprehensive analysis of transcriptomic profiling of 5-methylcytosin modification in placentas from preeclampsia and normotensive pregnancies

Quantitative Detection of the Hypermethylated RASSF1A Gene in Maternal Plasma of Pre-Eclampsia